BioXcel Stock Crashes 25% As Bid To Double Its Market Appears Less Certain

Shares of BTAI stock plummeted Thursday after BioXcel Therapeutics' (BTAI) Igalmi missed the mark in patients with agitation due to schizophrenia or bipolar disorders. X Igalmi is already approved for this use. But BioXcel is hoping to gain approval for at-home use of Igalmi. Today, a health care…#bioxceltherapeutics #igalmi #serenity #bioxcel #marketsmithcom #vimalmehta #allisongatlin #ibdagatlin #trackandbuy #bidtodouble
Source: Reuters: Health - Category: Consumer Health News Source Type: news